The poster child of Indian biotech world, Biocon, will soon return to the stock markets. The company is planning to list its contract research arm, Syngene, in the next 18 months. But Biocon chief, Kiran Majumdar Shaw says that she first wants to display sustainable growth before going for the IPO.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
